CB Scientific, Inc. (CBSC) Announces Corporate Name Change to Cardiac Biotech Solutions, Inc.
Cardiac Biotech Solutions, Inc. (OTC PINK:CBSC) announced its official name change from CB Scientific, Inc., effective May 7, 2025. The company, which specializes in non-invasive cardiac monitoring products, will retain its CBSC ticker symbol and CUSIP number. The company recently received FDA clearance for its MyCardia AT event monitor and is pursuing regulatory approvals in China through the NMPA and in Canada via Your Heart Protector Corp.
The MyCardia AT cardiac event monitor features a lightweight design and integrates with the AWS Cloud-based MyCardia portal and mobile applications across iOS and Android platforms. The company is working with international distribution partners in Southeast Asia, Hong Kong, and Macau for product launch.
Cardiac Biotech Solutions, Inc. (OTC PINK:CBSC) ha annunciato il cambio ufficiale del nome da CB Scientific, Inc., con effetto dal 7 maggio 2025. L'azienda, specializzata in prodotti per il monitoraggio cardiaco non invasivo, manterrà il simbolo ticker CBSC e il numero CUSIP. Recentemente ha ottenuto la approvazione FDA per il suo monitor per eventi cardiaci MyCardia AT e sta perseguendo le autorizzazioni regolatorie in Cina tramite la NMPA e in Canada attraverso Your Heart Protector Corp.
Il monitor per eventi cardiaci MyCardia AT presenta un design leggero e si integra con il portale MyCardia basato su cloud AWS e con le applicazioni mobili per piattaforme iOS e Android. L'azienda collabora con partner distributivi internazionali nel Sud-est asiatico, Hong Kong e Macao per il lancio del prodotto.
Cardiac Biotech Solutions, Inc. (OTC PINK:CBSC) anunció oficialmente el cambio de nombre desde CB Scientific, Inc., efectivo a partir del 7 de mayo de 2025. La compañía, especializada en productos de monitoreo cardíaco no invasivo, conservará el símbolo bursátil CBSC y el número CUSIP. Recientemente obtuvo la aprobación de la FDA para su monitor de eventos cardíacos MyCardia AT y está buscando aprobaciones regulatorias en China a través de la NMPA y en Canadá mediante Your Heart Protector Corp.
El monitor de eventos cardíacos MyCardia AT cuenta con un diseño liviano e integra el portal MyCardia basado en la nube AWS y aplicaciones móviles para plataformas iOS y Android. La empresa está trabajando con socios de distribución internacionales en el sudeste asiático, Hong Kong y Macao para el lanzamiento del producto.
Cardiac Biotech Solutions, Inc. (OTC PINK:CBSC)는 2025년 5월 7일부터 CB Scientific, Inc.에서 공식적으로 사명을 변경한다고 발표했습니다. 비침습 심장 모니터링 제품을 전문으로 하는 이 회사는 CBSC 티커 심볼과 CUSIP 번호를 유지할 예정입니다. 최근 MyCardia AT 이벤트 모니터에 대한 FDA 승인을 받았으며, 중국에서는 NMPA를 통해, 캐나다에서는 Your Heart Protector Corp.를 통해 규제 승인을 추진 중입니다.
MyCardia AT 심장 이벤트 모니터는 가벼운 디자인을 특징으로 하며 AWS 클라우드 기반 MyCardia 포털과 iOS 및 Android 플랫폼용 모바일 애플리케이션과 통합됩니다. 회사는 동남아시아, 홍콩, 마카오의 국제 유통 파트너들과 협력하여 제품 출시를 준비하고 있습니다.
Cardiac Biotech Solutions, Inc. (OTC PINK:CBSC) a annoncé son changement officiel de nom, passant de CB Scientific, Inc., à compter du 7 mai 2025. L'entreprise, spécialisée dans les produits de surveillance cardiaque non invasive, conservera son symbole boursier CBSC et son numéro CUSIP. Elle a récemment obtenu la validation de la FDA pour son moniteur d’événements cardiaques MyCardia AT et poursuit des approbations réglementaires en Chine via la NMPA et au Canada par l’intermédiaire de Your Heart Protector Corp.
Le moniteur d’événements cardiaques MyCardia AT se distingue par un design léger et s’intègre au portail MyCardia basé sur le cloud AWS ainsi qu’aux applications mobiles sur les plateformes iOS et Android. La société collabore avec des partenaires de distribution internationaux en Asie du Sud-Est, à Hong Kong et à Macao pour le lancement du produit.
Cardiac Biotech Solutions, Inc. (OTC PINK:CBSC) gab die offizielle Namensänderung von CB Scientific, Inc. bekannt, die am 7. Mai 2025 in Kraft tritt. Das Unternehmen, das sich auf nicht-invasive Herzüberwachungsprodukte spezialisiert hat, behält sein CBSC-Tickersymbol und die CUSIP-Nummer bei. Kürzlich erhielt das Unternehmen die FDA-Zulassung für seinen MyCardia AT Ereignismonitor und strebt regulatorische Genehmigungen in China über die NMPA sowie in Kanada über Your Heart Protector Corp. an.
Der MyCardia AT Ereignismonitor für das Herz zeichnet sich durch ein leichtes Design aus und ist in das AWS Cloud-basierte MyCardia-Portal sowie mobile Anwendungen für iOS- und Android-Plattformen integriert. Das Unternehmen arbeitet mit internationalen Vertriebspartnern in Südostasien, Hongkong und Macau für die Produkteinführung zusammen.
- FDA clearance obtained for MyCardia AT event monitor
- Expanding international market presence through distribution partnerships in Southeast Asia, Hong Kong, and Macau
- Active regulatory submission processes in China and Canada for market expansion
- Product integration with major platforms (AWS Cloud, iOS, Android) enhancing accessibility
- None.
LAS VEGAS, NV / ACCESS Newswire / May 8, 2025 / Cardiac Biotech Solutions, Inc. (OTC PINK:CBSC) ("CBSC" or the "Company"), a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products, announced today that the Company's name was changed to "Cardiac Biotech Solutions, Inc." effective May 7, 2025, following completion of the review of the Company's application to change its name by the Financial Industry Regulatory Authority (FINRA) and approval of the name change at the annual meeting of the Company's shareholders held on March 14, 2024. The name change will not impact the Company's current CBSC ticker symbol, nor will it affect the Company's assigned CUSIP number, the unique nine-digit identification number assigned to financial securities in the United States and Canada.
"We believe the name Cardiac Biotech Solutions more accurately reflects our core mission of advancing heart health," said Charles Martin, Chief Executive Officer of CBSC. "With FDA clearance now secured for our next-generation MyCardia AT event monitor, we are excited to move forward with a successful product launch in partnership with our established international distribution partners across Southeast Asia, Hong Kong, and Macau."
Additionally, the regulatory submission process for the MyCardia AT has resumed in collaboration with the Company's Chinese manufacturing partner, Shenzhen Pump, and representatives from the National Medical Products Administration (NMPA) in China, progressing toward market clearance. Concurrently, regulatory submission has also begun in Canada through our distribution partner, Your Heart Protector Corp., aiming to secure market approval across the Canadian healthcare landscape.
The MyCardia AT cardiac event monitor is designed to enhance the remote cardiac monitoring experience with its lightweight, easy-to-wear form factor and flexible options for transmitting event recordings. The device seamlessly integrates with the AWS Cloud-based MyCardia portal, as well as the widely adopted MyCardia mobile applications for iOS and Android. This ensures a cohesive and optimized user experience across global markets via smartphones and the MyCardia app on Apple, Google, or WeChat platforms.
As additional new developments occur, Cardiac Biotech Solutions, Inc. plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.
About Cardiac Biotech Solutions, Inc.
Cardiac Biotech Solutions, Inc., through its international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our electrocardiogram (EKG) devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.
Company Contact Information:
Telephone: (888) 225-0870
Investor Inquiries: investor@cardiacbiotech.com
Follow CBSC: X, Facebook, Instagram, LinkedIn, YouTube, and Newsletter
This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE: Cardiac Biotech Solutions, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the new name of CB Scientific Inc. (CBSC) and when is it effective?
Will CBSC stock symbol change after the company name change?
What is the MyCardia AT event monitor and what markets is it targeting?
What regulatory approvals has CBSC received for MyCardia AT?
